Merus is a buy with Bizengri approval for NRG1+ cancers, Petosemtamab's potential, and partnership with BHVN for oncology ...

Bezuclastinib's upcoming data in July 2025 could be a game-changer for COGT, offering a lucrative investment opportunity. See ...

Piers Morgan's show devolved into chaos Thursday after he cut the mic on a guest who bizarrely called him "sweetheart" and ...

Option Care gets 75% of its revenues from chronic therapies and 25% from acute treatments, but its growth now looks ...

Xenon has promising Phase 2 data for MDD treatment, robust financials, and a potential in niche markets, despite premium ...

Baltimore County Public Schools Superintendent Myriam Rogers presented a $2.98 billion total operating budget to the school ...

Researchers have discovered a biological mechanism that makes plant roots more welcoming to beneficial soil microbes.

Attruby's approval makes BridgeBio Pharma a competitor to Vyndaqel, with significant potential for growth and milestone ...

Read here for more on the potential of RCUS's combination therapies for various cancers, with promising Phase 3 trials and ...